<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34498">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02657473</url>
  </required_header>
  <id_info>
    <org_study_id>54939</org_study_id>
    <nct_id>NCT02657473</nct_id>
  </id_info>
  <brief_title>Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis</brief_title>
  <acronym>BATTLE</acronym>
  <official_title>Long-term Inhaled Nebulized Tobramycin in Patients With Non-cystic Fibrosis Bronchiectasis. A Randomized Placebo Controlled Trial. The BATTLE Study Bronchiectasis And Tobramycin SoluTion InhaLation ThErapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Center Alkmaar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Center Alkmaar</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of tobramycin inhalation solution (TIS)
      once daily compared tot placebo in patients with non-CF bronchiectasis. The primary endpoint
      is a reduction of exacerbations of the disease during the treatment period. Next to this
      parameter the investigators expect to show a significant beneficial effect on lung function
      parameters, QoL, bacterial load of pathogens in sputum and tobramycin resistance.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of exacerbations</measure>
    <time_frame>13 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Non-CF Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>TIS 300mg once daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tobramycin inhalation solution (TIS) 300mg once daily for a period of 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo once daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline 0.9% inhalation solution 300mg once daily for a period of 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tobramycin inhalation solution</intervention_name>
    <arm_group_label>TIS 300mg once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline 0.9% inhalation solution</intervention_name>
    <arm_group_label>Placebo once daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age â‰¥ 18 years

          2. The presence of chronic respiratory symptoms such as cough, dyspnoea, expectoration
             of sputum

          3. Confirmed non-CF bronchiectasis by (HR)CT

          4. Documented history of at least 2 pulmonary exacerbations treated with courses of
             antibiotics within 12 months before inclusion.

          5. No course of antibiotics or maintenance antibiotics (except for macrolides) 1 month
             prior to the start of the study.

          6. Minimal one documented sputum or BAL-fluid culture with gram-negative bacteria or
             S.aureus within 12 months.

          7. Growth of protocol defined pathogens in sputum at screening visit sensitive to
             tobramycin

          8. Tolerance of inhaled tobramycin

        Exclusion Criteria:

          1. Any exacerbation within the month prior to the start of the study

          2. Diagnosis of cystic fibrosis

          3. Active allergic bronchopulmonary aspergillosis (ABPA)

          4. Any oral, IV or inhaled antibiotics (except for macrolides) within 1 month prior to
             the start of the study

          5. Any IV or IM corticosteroids or change in oral corticosteroids (&gt; 10 mg) within 1
             month prior to the start of the study

          6. Any change/start treatment regimens macrolides, hypertonic saline, inhaled mannitol
             or other mucolytics, corticosteroids within 1 month prior to the start of the study

          7. Change in physiotherapy technique or schedule within 1 month prior to the start of
             the study

          8. Severe immunosuppression or active malignancy

          9. Active tuberculosis

         10. Chronic renal insufficiency (eGFR &lt; 30 ml/min), use of loop diuretics

         11. Have received an investigational drug or device within 1 month prior to the start of
             the study

         12. Serious or active medical or psychiatric illness

         13. Pregnancy and child bearing

         14. History of poor cooperation or non-compliance

         15. Unable to use nebulizers

         16. Allergic for tobramycin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wim G. Boersma, Dr.MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center Alkmaar</affiliation>
  </overall_official>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 8, 2016</lastchanged_date>
  <firstreceived_date>January 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical Center Alkmaar</investigator_affiliation>
    <investigator_full_name>W.G.Boersma</investigator_full_name>
    <investigator_title>Dr.MD.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
